PROFOUND MEDICAL CORP (PROF)
CA74319B5027 - Common Stock
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of...
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. ...
Profound Medical Announces Proposed Public Offering of Common Shares
Profound Medical Announces Proposed Public Offering of Common Shares
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024...
Profound Medical (PROF) Shares Cross Above 200 DMA
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
– Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and...
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’
TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’
TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the...
Profound Medical to Participate in the Stifel 2024 Healthcare Conference
Profound Medical to Participate in the Stifel 2024 Healthcare Conference
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Profound Medical Announces Third Quarter 2024 Financial Results
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code...
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes...
iAccess Alpha's Buyside Best Ideas Virtual Fall Conference September 24-25, 2024
Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA
Relative Strength Alert For Profound Medical
Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference
Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference
TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical...
PROF Crosses Below Key Moving Average Level
PROF Stock Earnings: Profound Medical Beats EPS, Misses Revenue for Q2 2024
PROF stock results show that Profound Medical beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
PROF Stock Earnings: Profound Medical Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Profound Medical (NASDAQ:PROF) just reported results for the second quarter of ...
Profound Medical Announces Second Quarter 2024 Financial Results
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Profound Medical Corp (PROF) Shares Cross Above 200 DMA
PROF Crosses Above Key Moving Average Level
Profound Medical Annual General Meeting of Shareholders Voting Results
Profound Medical Annual General Meeting of Shareholders Voting Results
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting...
PROFOUND MEDICAL ANNUAL GENERAL MEETING OF SHAREHOLDERS VOTING RESULTS
/CNW/ - Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General...
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training images – –...